B. Riley Securities Upgrades Kymera Therapeutics to Buy, Raises Price Target to $60

Benzinga · 06/03 13:52
B. Riley Securities analyst Kalpit Patel upgrades Kymera Therapeutics (NASDAQ:KYMR) from Neutral to Buy and raises the price target from $38 to $60.